Chargement en cours...
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
PURPOSE: A fixed-dose combination (FDC) of gemigliptin/rosuvastatin 50/20 mg as a monolayer tablet has been used to treat patients with both type 2 diabetes mellitus and dyslipidemia. To improve the stability of the FDC, a new FDC formulation as a bilayer tablet was developed. This study aimed to co...
Enregistré dans:
| Publié dans: | Drug Des Devel Ther |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7898221/ https://ncbi.nlm.nih.gov/pubmed/33628012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S288986 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|